Lodestone Wealth Management LLC Invests $8.37 Million in BioNTech SE (NASDAQ:BNTX)

Lodestone Wealth Management LLC has recently acquired a significant new stake in BioNTech SE (NASDAQ:BNTX), as reported in their latest 13F filing with the Securities and Exchange Commission (SEC). In the third quarter, Lodestone purchased 70,500 shares of the biopharmaceutical company at a substantial investment of approximately $8,373,000. This investment represents 4.1% of Lodestone's total holdings, making BioNTech their largest investment.

Recent Activity by Other Investors

Other institutional investors have also been active in adjusting their stakes in BioNTech. For instance, Covestor Ltd increased its position by 47.2% in the first quarter and now holds 415 shares worth about $38,000 after adding 133 shares. Blue Trust Inc. significantly raised its stake by 491.1% in the third quarter, acquiring 467 shares valued at $55,000 after purchasing an additional 388 shares. Similarly, EverSource Wealth Advisors LLC enhanced its holdings by 106.3% in the initial quarter, acquiring 489 shares worth around $43,000 after adding 252 shares. GAMMA Investing LLC also increased its position in BioNTech by 86.9% during the second quarter, with 512 shares worth approximately $41,000. Additionally, Crewe Advisors LLC made a new investment in BioNTech worth approximately $75,000. Collectively, institutional investors own about 15.52% of BioNTech's stock.

Performance of BioNTech Shares

As of last Friday, BioNTech's stock opened at $111.48. The market capitalization of the company stands at approximately $26.51 billion, with a price-to-earnings ratio of -49.33. The stock has a beta of 0.26, indicating lower volatility compared to the market. Over the past periods, the company's fifty-day moving average has been $109.72, while the 200-day moving average is noted at $95.77. BioNTech has recorded a quick ratio of 7.40 and a current ratio of 7.54, with a minimal debt-to-equity ratio of 0.01. Currently, the company’s stock price has ranged from a 52-week low of $76.53 to a high of $131.49.

Recent Earnings Report

Recently, BioNTech announced its quarterly earnings on August 5, which showed a loss of $3.36 per share, falling short of analysts' expectations of a loss of $2.02 by $1.34. The company reported a negative net margin of 18.69% and a return on equity of -2.54%. Their revenue for the quarter was $128.70 million, compared to the anticipated $134.98 million, reflecting a year-over-year decline of 23.3%. Analysts forecast that BioNTech SE will post -2.93 EPS for the current fiscal year.

Analyst Insights and Ratings Changes

A number of research firms have updated their rating and price targets for BioNTech shares. UBS Group raised its price target from $97.00 to $131.00 and maintained a "neutral" rating. Similarly, JPMorgan Chase & Co. upgraded their rating from "underweight" to "neutral," with a target price adjusted from $91.00 to $125.00. TD Cowen raised their target from $85.00 to $132.00 and also assigned a "hold" rating. Jefferies Financial Group increased their rating from "hold" to "buy," with a target price raised from $96.00 to $150.00. Lastly, HSBC increased their target from $97.00 to $136.00, classifying it as a "buy". Overall, five analysts have rated BioNTech as a hold, eight as a buy, and one as a strong buy, with an average rating of "Moderate Buy" and an average price target of $135.54.

Company Overview

BioNTech SE is a biotechnology company focused on developing and commercializing immunotherapies aimed at treating cancer and other infectious diseases. Their pipeline includes various product candidates like BNT111 for advanced melanoma and multiple others targeted toward different types of cancers.

investment, stocks, analysis